Screener
Prime Medicine PRME Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Prime Medicine in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Prime Medicine’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053883
| (in thousands) | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Cash flows used in operating activities: | ||
| Net loss | $(91,231) | $(104,481) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 9,509 | 12,006 |
| Non-cash lease expense | 5,709 | 4,761 |
| Depreciation expense | 3,641 | 3,564 |
| Amortization of premiums and discount on short-term investments | (743) | (575) |
| Change in fair value of short-term investment — related party | — | 1,561 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Prime Medicine's stock-based comp?
- Prime Medicine (PRME) reported stock-based comp of $4.87M in Q2 2026.
- How has Prime Medicine's stock-based comp changed year-over-year?
- Prime Medicine's stock-based comp decreased by 23.1% year-over-year, from $6.33M to $4.87M.
- What is the long-term trend for Prime Medicine's stock-based comp?
- Over 3 years (2022 to 2025), Prime Medicine's stock-based comp has grown at a 65.5% compound annual growth rate (CAGR), from $6.46M to $29.27M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Prime Medicine's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude